Introduction: Rationale for Combination Approaches
The integration of low-dose ketamine with existing pharmacological and psychotherapeutic treatments represents a clinical strategy aimed at optimizing therapeutic outcomes and extending the durability of ketamine's rapid-acting effects. Ketamine combination therapy operates on the premise that the transient nature of ketamine's antidepressant response -- typically lasting one to two weeks following a single infusion -- can be mitigated by concurrent treatments that consolidate and sustain the neuroplastic changes initiated by NMDA receptor modulation (Abdallah et al., 2015). This augmentation paradigm mirrors established practices in treatment-resistant depression, where combination pharmacotherapy and sequential treatment strategies are standard approaches to inadequate monotherapy response.
The pharmacological landscape of potential combination partners is complex, as multiple drug classes may interact with ketamine's mechanism of action -- either synergistically, additively, or antagonistically. Understanding these interactions at the molecular, receptor, and circuit levels is essential for designing rational combination protocols that maximize efficacy while minimizing adverse interactions. The existing evidence base, while growing, remains predominantly composed of secondary analyses from clinical trials, case series, and retrospective studies, with few prospective trials designed specifically to evaluate combination strategies.
Ketamine with Conventional Antidepressants
Serotonin Reuptake Inhibitors
The vast majority of patients receiving ketamine for depression are concurrently taking serotonin reuptake inhibitors (SSRIs or SNRIs), as most trials have permitted continuation of existing antidepressant regimens. Secondary analyses of major ketamine trials suggest that concurrent SSRI therapy does not significantly attenuate ketamine's acute antidepressant effect. Murrough and colleagues (2013) found no significant interaction between concurrent antidepressant class and ketamine response in a post-hoc analysis, published in Biological Psychiatry.
At the mechanistic level, SSRIs and ketamine target largely non-overlapping neurotransmitter systems -- serotonin reuptake inhibition versus NMDA receptor antagonism -- suggesting pharmacological compatibility. However, both ultimately converge on common downstream targets including BDNF expression and hippocampal neuroplasticity, raising the possibility of synergistic effects on neuroplastic endpoints even in the absence of receptor-level interaction (Duman and Aghajanian, 2012).
Tricyclic Antidepressants and MAOIs
Tricyclic antidepressants (TCAs) present specific pharmacological considerations in combination with ketamine. TCAs inhibit norepinephrine and serotonin reuptake and also block sodium channels and muscarinic receptors. The sympathomimetic effects of ketamine combined with norepinephrine reuptake inhibition may produce additive hemodynamic effects (blood pressure elevation, tachycardia), necessitating enhanced cardiovascular monitoring.
Monoamine oxidase inhibitors (MAOIs) represent the most significant interaction concern. By inhibiting monoamine catabolism, MAOIs increase synaptic norepinephrine and serotonin levels. Ketamine's sympathomimetic properties, combined with MAOI-induced catecholamine accumulation, create a theoretical risk of hypertensive crisis. While this interaction is largely theoretical at sub-anesthetic ketamine doses and no cases have been published, most clinical protocols consider MAOI use a relative contraindication or mandate enhanced blood pressure monitoring (Sanacora et al., 2017). For a comprehensive review of all relevant medication interactions, see the drug interactions guide.
Ketamine with Mood Stabilizers
Lithium
The combination of ketamine with lithium has received specific research attention due to overlapping mechanisms relevant to antidepressant response. Both agents modulate glycogen synthase kinase-3 beta (GSK-3beta) -- lithium through direct inhibition and ketamine indirectly through Akt-mediated phosphorylation (Beurel et al., 2011). This mechanistic convergence led to the hypothesis that lithium might sustain ketamine's antidepressant effect by maintaining GSK-3beta inhibition after ketamine's direct pharmacological effects dissipate.
Mathew and colleagues (2010), in a randomized placebo-controlled trial published in Biological Psychiatry, tested this hypothesis by randomizing ketamine responders to lithium or placebo following successful single infusion. The results were negative -- lithium did not significantly extend the duration of ketamine's antidepressant response relative to placebo. However, the study was small (n=36), lithium was initiated after ketamine response (rather than being established beforehand), and therapeutic lithium levels may not have been achieved within the study timeframe. The negative result has not been considered definitive, and some experts suggest that pre-established lithium therapy at therapeutic levels (0.6-1.0 mEq/L) may produce different results than lithium initiation post-ketamine.
Valproate and Lamotrigine
Valproate and lamotrigine -- both widely used mood stabilizers with anticonvulsant properties -- have been co-administered with ketamine in bipolar depression trials. In the Diazgranados et al. (2010) study, concurrent valproate or lithium was required, and ketamine demonstrated robust antidepressant efficacy in this context. No significant pharmacokinetic interactions between ketamine and valproate have been identified.
Lamotrigine presents a more nuanced pharmacological interaction. As a voltage-gated sodium channel blocker that inhibits presynaptic glutamate release, lamotrigine may attenuate the glutamate surge that is hypothesized to initiate ketamine's antidepressant signaling cascade. Anand and colleagues (2000) demonstrated that pre-treatment with lamotrigine reduced ketamine's psychotomimetic effects in healthy volunteers, suggesting modulation of the downstream pharmacodynamic response. Whether lamotrigine attenuates ketamine's antidepressant effect -- or merely its side effects -- remains unresolved. Some clinicians empirically observe reduced ketamine efficacy in patients taking lamotrigine, but this observation has not been confirmed in controlled studies (McGirr et al., 2017).
Ketamine with Benzodiazepines
The Attenuation Concern
The potential interaction between benzodiazepines and ketamine has generated significant clinical concern. Benzodiazepines enhance GABAergic inhibition, and ketamine's antidepressant mechanism is hypothesized to involve disinhibition of glutamatergic pyramidal neurons via preferential NMDA receptor blockade on GABAergic interneurons. If benzodiazepines counteract this disinhibition by globally enhancing GABAergic tone, they could theoretically attenuate ketamine's therapeutic effect (Frye et al., 2015).
Frye and colleagues (2015) reported a post-hoc analysis suggesting that concurrent benzodiazepine use was associated with reduced ketamine antidepressant response, published in Journal of Clinical Psychopharmacology. However, this finding has not been consistently replicated. Andrashko and colleagues (2020) conducted a systematic analysis and concluded that the evidence for benzodiazepine attenuation of ketamine's antidepressant effect is inconclusive, with some studies finding no significant interaction. The observed association may be confounded by greater illness severity in benzodiazepine-treated patients.
Clinical Implications
Despite the uncertain evidence, many ketamine clinics advise patients to withhold benzodiazepines on the day of infusion when clinically safe to do so. This pragmatic approach aims to minimize potential pharmacodynamic interference while acknowledging the inconclusive evidence base. For patients who cannot safely discontinue benzodiazepines (those with high-dose dependence or seizure risk), ketamine administration with concurrent benzodiazepine use remains reasonable, with awareness that response may be attenuated.
Ketamine with Atypical Antipsychotics
Atypical antipsychotics are commonly prescribed in treatment-resistant depression, either as primary treatment (for bipolar depression) or as augmentation agents (aripiprazole, quetiapine, olanzapine-fluoxetine combination). Their interaction with ketamine involves multiple receptor systems. Most atypical antipsychotics are D2 receptor antagonists, and ketamine has weak D2 agonist properties at higher concentrations -- suggesting possible pharmacodynamic opposition. However, at sub-anesthetic doses, ketamine's D2 activity is minimal and unlikely to produce clinically significant interaction.
Clozapine, which possesses unique glutamatergic modulating properties including glycine transporter inhibition, presents a theoretically interesting combination partner. By increasing glycine availability at the NMDA receptor glycine co-agonist site, clozapine could modify ketamine's NMDA receptor interaction -- though the net effect is difficult to predict. No clinical data specifically address the ketamine-clozapine combination, and this represents an unexplored research opportunity.
Ketamine with Psychotherapy
Cognitive-Behavioral Therapy Integration
The integration of ketamine with cognitive-behavioral therapy (CBT) represents one of the most promising combination strategies, grounded in the hypothesis that ketamine-induced neuroplasticity creates windows of enhanced learning and memory consolidation during which psychotherapeutic interventions may be more effective (Wilkinson et al., 2017). The neurobiological basis for this hypothesis includes ketamine-induced increases in BDNF, synaptogenesis in the prefrontal cortex, and enhanced long-term potentiation -- all processes that support the encoding and consolidation of new cognitive and behavioral patterns.
Wilkinson and colleagues (2017) proposed a model in which CBT sessions are strategically timed to occur during the 24-72 hour window following ketamine infusion, when neuroplastic enhancement is hypothesized to be maximal. Preliminary data from pilot studies suggest that this sequential approach may improve the durability of both ketamine's antidepressant effect and CBT's therapeutic gains, though randomized controlled trials are needed.
Behavioral Activation and Exposure Therapies
Behavioral activation -- a component of CBT that targets anhedonia and withdrawal through scheduled engagement in rewarding activities -- may be particularly well-suited for combination with ketamine. Ketamine rapidly improves anhedonia in many patients (Lally et al., 2014), potentially lowering the motivational threshold for behavioral engagement. Capitalizing on this window of reduced anhedonia by initiating behavioral activation protocols during the acute post-infusion period could consolidate behavioral changes that persist beyond ketamine's direct pharmacological effect.
For anxiety-predominant presentations, the combination of ketamine with exposure therapy leverages the plasticity-enhancing properties of ketamine to facilitate fear extinction learning -- analogous to established D-cycloserine augmentation protocols but with potentially greater magnitude of plasticity enhancement (Girgenti et al., 2017).
Pharmacological Consolidation Strategies
Rapamycin
A provocative pharmacological approach involves co-administration of rapamycin -- an mTORC1 inhibitor -- with ketamine. This strategy is paradoxical, as ketamine's antidepressant mechanism is hypothesized to involve mTORC1 activation. However, Abdallah and colleagues (2020), published in Neuropsychopharmacology, demonstrated in a randomized trial that pre-treatment with oral rapamycin (6 mg) extended the duration of ketamine's antidepressant effect, with the rapamycin-ketamine group maintaining response for significantly longer than ketamine alone. The proposed mechanism involves rapamycin-induced autophagy of dysfunctional synapses, creating a "clean slate" for ketamine-driven synaptogenesis. This finding, if replicated, could represent a paradigm-shifting consolidation strategy.
Scopolamine
Scopolamine, a muscarinic acetylcholine receptor antagonist with rapid antidepressant properties, has been explored as a combination agent with ketamine. Both agents produce rapid antidepressant effects through distinct but potentially complementary mechanisms -- ketamine via NMDA receptor blockade and scopolamine via M1/M2 muscarinic receptor antagonism (Drevets et al., 2013). Whether sequential or concurrent administration produces synergistic antidepressant effects has not been systematically studied.
Evidence Gaps and Future Directions
The evidence base for ketamine combination therapy is characterized by significant gaps. Most existing data derive from secondary analyses rather than prospectively designed combination studies. Key research priorities include randomized trials comparing ketamine monotherapy versus ketamine augmented with specific drug classes, timing optimization studies for psychotherapy integration, and mechanistically informed combination designs targeting specific molecular pathways.
Biomarker-guided combination selection -- using neuroimaging, genetic, or peripheral biomarkers to predict which patients will benefit from specific combination strategies -- represents an aspirational but potentially transformative approach. As the field matures, the development of evidence-based clinical algorithms for ketamine combination therapy will be essential for optimizing outcomes in treatment-resistant populations.
Conclusion
Ketamine combination therapy encompasses a diverse array of pharmacological and psychotherapeutic augmentation strategies aimed at optimizing and sustaining the rapid-acting antidepressant response. The current evidence suggests that concurrent SSRI therapy is compatible with ketamine efficacy, benzodiazepines may attenuate response (though evidence is inconclusive), and mood stabilizers provide essential safety coverage in bipolar populations. The most promising emerging approaches include strategically timed psychotherapy integration, rapamycin-based consolidation, and combined pharmacological-behavioral activation protocols. Prospective randomized trials designed specifically to evaluate combination strategies represent a critical need for advancing evidence-based clinical practice.
References
- NIMH: Depression Overview — National Institute of Mental Health clinical information on depression treatment strategies
- DailyMed: FDA Drug Label Information — National Library of Medicine database of FDA-approved drug labeling for ketamine and concurrent medications
- PubMed: Ketamine-Assisted Psychotherapy: Systematic Narrative Review — Systematic review of evidence for combining ketamine with psychotherapeutic modalities
- MedlinePlus: Ketamine Injection Drug Information — National Library of Medicine medication information including drug interaction considerations
Share